Nantong Jinghua Pharmaceutical Co Ltd (002349) - Total Liabilities
Based on the latest financial reports, Nantong Jinghua Pharmaceutical Co Ltd (002349) has total liabilities worth CN¥392.26 Million CNY (≈ $57.40 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Nantong Jinghua Pharmaceutical Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Nantong Jinghua Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 002349 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Nantong Jinghua Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nantong Jinghua Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cablevision Holding SA
BA:CVH
|
Argentina | AR$9.10 Trillion |
|
Dan Hotels
TA:DANH
|
Israel | ILA1.30 Billion |
|
Zenner Metering Technology (Shanghai) Ltd. A
SHE:301303
|
China | CN¥1.09 Billion |
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr653.00 Million |
|
Warom Technology Inc Co
SHG:603855
|
China | CN¥2.72 Billion |
|
Allis Electric Co Ltd
TW:1514
|
Taiwan | NT$7.29 Billion |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
China | CN¥801.76 Million |
|
Cello World Limited
NSE:CELLO
|
India | Rs2.64 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Nantong Jinghua Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nantong Jinghua Pharmaceutical Co Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nantong Jinghua Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nantong Jinghua Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Nantong Jinghua Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥421.13 Million ≈ $61.62 Million |
+22.19% |
| 2024-12-31 | CN¥344.66 Million ≈ $50.43 Million |
-9.48% |
| 2023-12-31 | CN¥380.75 Million ≈ $55.72 Million |
-8.90% |
| 2022-12-31 | CN¥417.93 Million ≈ $61.16 Million |
-33.51% |
| 2021-12-31 | CN¥628.54 Million ≈ $91.98 Million |
-6.09% |
| 2020-12-31 | CN¥669.29 Million ≈ $97.94 Million |
-15.67% |
| 2019-12-31 | CN¥793.62 Million ≈ $116.13 Million |
+12.53% |
| 2018-12-31 | CN¥705.27 Million ≈ $103.20 Million |
+18.64% |
| 2017-12-31 | CN¥594.47 Million ≈ $86.99 Million |
+160.88% |
| 2016-12-31 | CN¥227.87 Million ≈ $33.34 Million |
-16.31% |
| 2015-12-31 | CN¥272.27 Million ≈ $39.84 Million |
-22.64% |
| 2014-12-31 | CN¥351.96 Million ≈ $51.50 Million |
+6.98% |
| 2013-12-31 | CN¥328.99 Million ≈ $48.14 Million |
+35.47% |
| 2012-12-31 | CN¥242.84 Million ≈ $35.54 Million |
+68.37% |
| 2011-12-31 | CN¥144.23 Million ≈ $21.11 Million |
+115.39% |
| 2010-12-31 | CN¥66.96 Million ≈ $9.80 Million |
-19.57% |
| 2009-12-31 | CN¥83.26 Million ≈ $12.18 Million |
+7.72% |
| 2008-12-31 | CN¥77.29 Million ≈ $11.31 Million |
-28.60% |
| 2007-12-31 | CN¥108.25 Million ≈ $15.84 Million |
-15.55% |
| 2006-12-31 | CN¥128.18 Million ≈ $18.76 Million |
-- |
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and… Read more